Teva Pharma (TEVA) Tops Q2 EPS by 12c; Boosts FY15 EPS Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Teva Reports Strong Second Quarter 2015 Results and Raises Guidance for Full-Year 2015
July 30, 2015 7:00 AM EDTRevenues of $5.0 billion, in line with the second quarter of 2014. Non-GAAP operating income of $1.6 billion, an increase of 16% compared to the second quarter of 2014. GAAP operating income of $662 million, down 28%. Non-GAAP net income of $1.2 billion, up 15% compared to the second quarter of 2014. GAAP net income of $539 million, a decrease of 28%. Quarterly non-GAAP EPS of $1.43, an increase of 14% compared to the second quarter of 2014. GAAP diluted EPS of $0.63, a decrease of 28%. Strong cash flow from operations of $1.5 billion, an increase of 41%... More
